Well, fortunately or unfortunately, we're not scientists at this table. We're policy-makers, and I think the task before us is to try to provide good public policy to determine which Canadians are entitled to compensation. It seems to me that.... Just in this meeting, I've written down a number of symptoms that are associated with thalidomide embryopathy: extra digits, webbing, cysts or ganglia, shortened limbs, inflammation, bowel or bladder issues, gastrointestinal issues, certain cardiac issues, hearing loss, small jaw....
If we're trying to figure out if it's likely that someone was a victim of thalidomide, would it not make sense that if they were born in a place in Canada at a time when thalidomide was being dispensed, if they're in a region where it was being dispensed, if they present to a doctor with not just a hole in the heart—your example is well taken—but a cluster of symptoms, and if they have a number of the symptoms in this cluster, we can be reasonably sure that cluster was likely caused by thalidomide and then qualify them for compensation? If you add in the genetic testing, wouldn't that be a reasonable approach, perhaps not with scientific certainty, but as a policy-maker?